Evidence map›Paper›PMID 24866342›Full record

ArticleCell cycle (Georgetown, Tex.)2014

Cellular senescence and protein degradation: breaking down cancer.

Xavier Deschênes-Simard, Frédéric Lessard, Marie-France Gaumont-Leclerc, Nabeel Bardeesy, Gerardo Ferbeyre

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. The Downregulation of Both Giant HERCs,Journal of clinical medicine · 2022
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xavier Deschênes-SimardDepartment of Biochemistry and Molecular Medicine; Université de Montréal; Montréal, Québec, Canada.
Frédéric LessardDepartment of Biochemistry and Molecular Medicine; Université de Montréal; Montréal, Québec, Canada.
Marie-France Gaumont-LeclercDepartment of Biochemistry and Molecular Medicine; Université de Montréal; Montréal, Québec, Canada.
Nabeel BardeesyMassachusetts General Hospital Cancer Center; Harvard Medical School; Boston, MA USA.
Gerardo FerbeyreDepartment of Biochemistry and Molecular Medicine; Université de Montréal; Montréal, Québec, Canada.
Université de Montréal · CAHarvard University · US

Funding

The RAS and P13K Pathways in Pancreatic AdenocarcinomaP01CA117969 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI DEPINHO, RONALD ANTHONY · 2006 to 2025
$41.7M
TGF-beta Signaling in Pancreatic CancerR01CA133557 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI EL-BARDEESY, NABEEL · 2008 to 2013
$1.7M
NCI NIH HHS P01 CA117969NCI NIH HHS P01 CA117969-07NCI NIH HHS R01 CA133557NCI NIH HHS R01 CA133557-05
6 · The paper itself

Abstract

Autophagy and the ubiquitin-proteasome pathway (UPP) are the major protein degradation systems in eukaryotic cells. Whereas the former mediate a bulk nonspecific degradation, the UPP allows a rapid degradation of specific proteins. Both systems have been shown to play a role in tumorigenesis, and the interest in developing therapeutic agents inhibiting protein degradation is steadily growing. However, emerging data point to a critical role for autophagy in cellular senescence, an established tumor suppressor mechanism. Recently, a selective protein degradation process mediated by the UPP was also shown to contribute to the senescence phenotype. This process is tightly regulated by E3 ubiquitin ligases, deubiquitinases, and several post-translational modifications of target proteins. Illustrating the complexity of UPP, more than 600 human genes have been shown to encode E3 ubiquitin ligases, a number which exceeds that of the protein kinases. Nevertheless, our knowledge of proteasome-dependent protein degradation as a regulated process in cellular contexts such as cancer and senescence remains very limited. Here we discuss the implications of protein degradation in senescence and attempt to relate this function to the protein degradation pattern observed in cancer cells.

Indexed as

Cellular SenescenceProteolysisAutophagyCell Cycle CheckpointsCell NucleolusDNA DamageHumansNeoplasmsProteomeRibosomesRNA, MessengerUbiquitin-Protein LigasesProteomeRNA, MessengerUbiquitin-Protein LigasesE3 ligasesERK kinasesRas oncogeneSASPubiquitin

Identifiers

PMID24866342
PMCPMC4111748
OpenAlexW2316200901

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.